{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.6","upperLimit":"6.2","value":"4.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"Progression Free Survival is defined as the time from registration to the earliest date documentation of disease progression or death. The distribution of time to disease progression will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"This endpoint was analyzed using all patients treated at the MTD (Dose Level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day). This includes the eligible Phase I participants treated at Dose Level 1 (N=5) and it includes all participants treated in Phase II (N=77).","id":"OG000","title":"Sorafenib 200 mg Twice Daily, RAD001 5mg Every Day"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 3 years from registration","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}